“It is a game changer,” says Ian Neeland, MD, Director of Cardiovascular Prevention at University Hospitals Harrington Heart & Vascular Institute.
“We’ve known that low-grade, systemic inflammation is a powerful determinant of recurrent cardiovascular events. Colchicine is the first drug we have on the market for inflammation that reduces this risk,” says Dr. Neeland."
Click on the link below for the details:
No comments:
Post a Comment